Clinical Evaluation of the Heparin Therapeutic Window Using Activated Clotting Time in Neurological Interventional Radiology at an Academic Medical Center.

Melody B Nelson, Amitava Dasgupta, X Long Zheng
{"title":"Clinical Evaluation of the Heparin Therapeutic Window Using Activated Clotting Time in Neurological Interventional Radiology at an Academic Medical Center.","authors":"Melody B Nelson, Amitava Dasgupta, X Long Zheng","doi":"10.5858/arpa.2024-0399-OA","DOIUrl":null,"url":null,"abstract":"<p><strong>Context.—: </strong>Activated clotting time (ACT) is useful for monitoring heparin therapy in neurointerventional radiology (NIR). We previously used the Hemochron Signature Elite instrument for measuring ACT in NIR.</p><p><strong>Objective.—: </strong>To evaluate the suitability of measuring ACT using i-STAT in NIR by comparing its performance with Hemochron and a laboratory-based anti-Xa (anti-factor Xa) assay.</p><p><strong>Design.—: </strong>All ACT measurements were performed in duplicate, using 2 Hemochron and 2 i-STAT devices in 53 samples from 15 unique multidose heparin administrations in NIR procedures and 110 samples in cardiovascular procedures. Samples were tested simultaneously within 1 minute of each other.</p><p><strong>Results.—: </strong>For 12 of the 15 procedures in NIR, anti-Xa was assessed at the beginning of the procedure and at the end of all procedural dosing. We also reviewed the patient's charts anonymously for any indication of postprocedural neurological bleeding. Interinstrument variability was much higher with Hemochron than with i-STAT. We also observed lower ACT values with i-STAT than with Hemochron. Therefore, the historical ACT range of 250 to 300 seconds for Hemochron was revised to 200 to 250 seconds for i-STAT devices. In the therapeutic window for anti-Xa, ACT results from both instruments exhibited a linear correlation. However, at supratherapeutic range for anti-Xa, ACT results from Hemochron exhibited more linear correlation, while i-STAT ACT demonstrated a plateau effect. No patient had any evidence of severe postprocedural neurological bleeding.</p><p><strong>Conclusions.—: </strong>The i-STAT analyzers produce more reproducible ACT results, but the target range should be lowered to 200 to 250 seconds. This range appears to provide adequate and safe heparin therapy, confirmed by anti-Xa assay results and clinical outcome.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology & laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5858/arpa.2024-0399-OA","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Context.—: Activated clotting time (ACT) is useful for monitoring heparin therapy in neurointerventional radiology (NIR). We previously used the Hemochron Signature Elite instrument for measuring ACT in NIR.

Objective.—: To evaluate the suitability of measuring ACT using i-STAT in NIR by comparing its performance with Hemochron and a laboratory-based anti-Xa (anti-factor Xa) assay.

Design.—: All ACT measurements were performed in duplicate, using 2 Hemochron and 2 i-STAT devices in 53 samples from 15 unique multidose heparin administrations in NIR procedures and 110 samples in cardiovascular procedures. Samples were tested simultaneously within 1 minute of each other.

Results.—: For 12 of the 15 procedures in NIR, anti-Xa was assessed at the beginning of the procedure and at the end of all procedural dosing. We also reviewed the patient's charts anonymously for any indication of postprocedural neurological bleeding. Interinstrument variability was much higher with Hemochron than with i-STAT. We also observed lower ACT values with i-STAT than with Hemochron. Therefore, the historical ACT range of 250 to 300 seconds for Hemochron was revised to 200 to 250 seconds for i-STAT devices. In the therapeutic window for anti-Xa, ACT results from both instruments exhibited a linear correlation. However, at supratherapeutic range for anti-Xa, ACT results from Hemochron exhibited more linear correlation, while i-STAT ACT demonstrated a plateau effect. No patient had any evidence of severe postprocedural neurological bleeding.

Conclusions.—: The i-STAT analyzers produce more reproducible ACT results, but the target range should be lowered to 200 to 250 seconds. This range appears to provide adequate and safe heparin therapy, confirmed by anti-Xa assay results and clinical outcome.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Primary Angiitis of the Central Nervous System and Its Mimics: A Pattern-Based Approach to Biopsies for Central Nervous System Vasculitis. Evaluation of Laboratory-Derived Immunohistochemical Assays for Folate Receptor α Expression in Epithelial Ovarian Cancer and Comparison With a Companion Diagnostic. Breast Cancer Biopsies With Group 2 and Group 4 Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization Results Should Have Repeated Testing on Excision. Diagnosis and Prevention of Transition Zone Pull-through in Patients With Hirschsprung Disease. Clinical Evaluation of the Heparin Therapeutic Window Using Activated Clotting Time in Neurological Interventional Radiology at an Academic Medical Center.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1